Loading...

LENZ LENZ THERAPEUTICS INC Product Launches 8-K Filing

LNZ

LNZ

LENZ THERAPEUTICS INC

(LENZ)

2025 8-K

Safety Report Update

Financial Results Released

Stock Sale Completed

Product Launch Announcement

New Product Launches

Financial Statements

Earnings Releases

Financial Update

Financial Results

Financial Results

Clinical Trial Data

Financial Results

FDA Application

Private Placement

Earnings Reports

Press Release and Corporate...

Merger Agreement and Name C...

Merger Agreement

Dividend Announcement

Merger Agreement

Merger Agreement

Merger Agreement

Sublease Agreement

Appointment and Restructuring

Appointment of Director

Resignation of CFO

Earnings Reports

Retention Agreements

Costs Associated with Exit ...

Announcement of Voluntary P...

External Links:

LENZ Therapeutics, Inc. announced on September 30, 2025, the availability of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia treatment, with commercial shipments starting in October 2025.

AI Assistant

LENZ THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.